Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

318 ARTÍCULOS , VIENDO DEL 91 AL 105

The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation

Anand A, Banik A, Thakur K, Masters CL.

Curr Alzheimer Res. 2012 Nov;9(9):1010-29. doi: 10.2174/156720512803569055.

Effects of polyphenols on brain ageing and Alzheimer's disease: focus on mitochondria

Schaffer S, Asseburg H, Kuntz S, Muller WE, Eckert GP.

Mol Neurobiol. 2012 Aug;46(1):161-78. doi: 10.1007/s12035-012-8282-9. Epub 2012 Jun 17.

Colombia at the centre of preclinical AD research

Lancet Neurol. 2012 Jul;11(7):567. doi: 10.1016/S1474-4422(12)70144-8.

γ-Secretase modulator in Alzheimer's disease: shifting the end

Xia W, Wong ST, Hanlon E, Morin P.

J Alzheimers Dis. 2012;31(4):685-96. doi: 10.3233/JAD-2012-120751.

Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia

Allegri RF, Guekht A.

Drugs Today (Barc). 2012 Apr;48 Suppl A:25-41. doi: 10.1358/dot.2012.48(Suppl.A).1739721.

The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery

Sharma HS, Castellani RJ, Smith MA, Sharma A.

Int Rev Neurobiol. 2012;102:47-90. doi: 10.1016/B978-0-12-386986-9.00003-X.

Immunotherapy for Alzheimer disease: the challenge of adverse effects

Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ.

Nat Rev Neurol. 2012 Aug;8(8):465-9. doi: 10.1038/nrneurol.2012.118. Epub 2012 Jul 3.

Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial

Scheltens P, Twisk JW, Blesa R, Scarpini E, von Arnim CA, Bongers A, Harrison J, Swinkels SH, Stam CJ, de Waal H, Wurtman RJ, Wieggers RL, Vellas B, Kamphuis PJ.

J Alzheimers Dis. 2012;31(1):225-36. doi: 10.3233/JAD-2012-121189.

Heat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer's disease

Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, Shim JY, Kim M.

Nutr Neurosci. 2012 Nov;15(6):278-82. doi: 10.1179/1476830512Y.0000000027.

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ

Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ.

J Neurosci. 2012 Jul 11;32(28):9677-89. doi: 10.1523/JNEUROSCI.4742-11.2012.

Insulin: an emerging treatment for Alzheimer's disease dementia?

Morris JK, Burns JM.

Curr Neurol Neurosci Rep. 2012 Oct;12(5):520-7. doi: 10.1007/s11910-012-0297-0.

Continuing donepezil produces cognitive benefits in Alzheimer's

Bland P.

Practitioner. 2012 Apr;256(1750):5.

Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease

Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, Kressig RW, Downs P, Caputo A, Strohmaier C.

Dement Geriatr Cogn Disord. 2012;33(5):341-53. doi: 10.1159/000340056. Epub 2012 Jul 11.

Potential use of γ-secretase modulators in the treatment of Alzheimer disease

Wagner SL, Tanzi RE, Mobley WC, Galasko D.

Arch Neurol. 2012 Oct;69(10):1255-8. doi: 10.1001/archneurol.2012.540.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias